We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lilly Acquires Chronic Pain Medicine in Potential $950 Million Deal

Lilly Acquires Chronic Pain Medicine in Potential $950 Million Deal

June 4, 2019

Eli Lilly agreed to pay up to $47.5 million up front for Centrexion’s chronic pain treatment currently in Phase I trials.

The deal could be worth up to $575 million if Centrexion’s CNTX-0290 hits its development and regulatory milestones and another $375 million if the drug is approved and reaches certain sales milestones.

CNTX-0290 is a small molecule somatostatin receptor type 4 agonist developed to treat chronic pain—and most important, isn’t an opioid and isn’t addictive.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Clearancestamp_gray

    FDA Clears Lymphedema Assessment Platform for Expanded Indication

  • Herontherapeutics_logo

    Health Canada Grants Priority Review for Heron’s Non-Opioid Pain Treatment

  • Fda_logo_blue_2016

    Senate Confirms Stephen Hahn as Next FDA Commissioner

  • Healthcanada_logo

    Health Canada Approves Boehringer Ingelheim’s Ofev for Systemic Sclerosis

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing